SB504: (New Title) relative to the practice of pharmacy and the dispensing of certain medications by pharmacists, authorizing the establishment of experimental treatment centers, and permitting treatment of certain severe illness under the right to try act.

Related law links

RSA references from bill data

• 126-A:84 · add · effective 2027-01-01

  n amount equal to at least 2 percent of the center’s net annual profits the uncompensated care fund established under RSA 167:64, the opioid abatement trust fund established under RSA 126-A:84, the alcohol abuse prevention and treatment fund established under RSA 176-A:1, the lead paint poisoning control fund established under RSA 130-A:15, or any fund to benefit the developmentally disabled established under

• 126-Z · reference · effective 2027-01-01

  nt, if applicable, that patient is liable for treatment expenses; and (6) A prominent statement that the patient is seeking treatment from an experimental treatment center under RSA 126-ZZ. II. “Experimental treatment” means the provision of a medical intervention by a health care provider involving an investigational drug, biologic, or device that has successfully completed phase one of a clinical t

• 126-Z:1 · amend · effective 2027-01-01

  ith all review and patient protection standards described therein, it shall not be required to obtain a license except as provided in that chapter. 17 Right to Try Act. Amend RSA 126-Z:1 through 126-Z:4 to read as follows: 126-Z:1 Definitions. In this chapter: I. "Eligible facility" means a licensed New Hampshire institution that is operating under a Federalwide Assurance ("FWA") for the Protec

• 126-Z:3 · reference · effective 2027-01-01

  ce [to eligible patients pursuant to this chapter. A manufacturer may:] not approved by the United States Food and Drug Administration available to patients if the requirements of RSA 126-Z:3, III are satisfied. I-a. Pursuant to this chapter, a manufacturer may: (a) Provide [an investigational] a drug, biologic, or device to [an eligible] a patient without receiving compensation. (b) Require [an el

• 126-Z:6 · amend · effective 2027-01-01

  r court for injunctive relief and reasonable attorney's fees against any regulatory or law enforcement authority that violates this chapter. 18 Telehealth Prescreening. Amend RSA 126-Z:6, I to read as follows: I. Notwithstanding any regulation or provision of law to the contrary, any health care provider, while physically located in New Hampshire, may conduct a telehealth prescreening with any patie

• 126-Z:8 · amend · effective 2027-01-01

  screening with any patient, in any state or jurisdiction, who has been diagnosed by a physician with a terminal or qualifying severe illness. 19 Statutory Construction. Amend RSA 126-Z:8 to read as follows: 126-Z:8 Statutory Construction. The general court enacts this chapter to promote maximum access by removing barriers in state law and indemnifying those involved in providing potentially life-sa

• 130-A:15 · add · effective 2027-01-01

  t trust fund established under RSA 126-A:84, the alcohol abuse prevention and treatment fund established under RSA 176-A:1, the lead paint poisoning control fund established under RSA 130-A:15, or any fund to benefit the developmentally disabled established under RSA 171-A:8-b, provided that the department may adjudicate in a rulemaking under RSA 541-A that one or more of these funds is functionally inactive

• 151 · reference · effective 2027-01-01

  der this chapter. II. Notwithstanding any provision of law to the contrary, the department of health and human services shall not take action against a provider licensed under RSA 151, or any other law, based primarily on the institution's participation in treatment authorized under this chapter. 126-ZZ:5 Experimental Treatment Center Licensing. I. A provider seeking to provide experimental t

• 151:2 · reference · effective 2027-01-01

  ers experimental therapies pursuant to RSA 126-ZZ:3. An entity’s status as an experimental treatment center under this chapter is legally distinct from its licensing status under RSA 151:2, its administration of any treatments under 126-Z, and its participation in other protected access. IV. “Other protected access” includes expanded access or compassionate use, in which the treating physician has req

• 167:64 · add · effective 2027-01-01

  nt of the center’s net annual profits; or (b) Contributing an amount equal to at least 2 percent of the center’s net annual profits the uncompensated care fund established under RSA 167:64, the opioid abatement trust fund established under RSA 126-A:84, the alcohol abuse prevention and treatment fund established under RSA 176-A:1, the lead paint poisoning control fund established under RSA 130-A:15, or an

• 171-A:8-B · add · effective 2027-01-01

  ent fund established under RSA 176-A:1, the lead paint poisoning control fund established under RSA 130-A:15, or any fund to benefit the developmentally disabled established under RSA 171-A:8-b, provided that the department may adjudicate in a rulemaking under RSA 541-A that one or more of these funds is functionally inactive and therefore ineligible to satisfy the requirements of this provision. III. The

• 176-A:1 · add · effective 2027-01-01

  mpensated care fund established under RSA 167:64, the opioid abatement trust fund established under RSA 126-A:84, the alcohol abuse prevention and treatment fund established under RSA 176-A:1, the lead paint poisoning control fund established under RSA 130-A:15, or any fund to benefit the developmentally disabled established under RSA 171-A:8-b, provided that the department may adjudicate in a rulemaking und

• 318 · reference · effective 2027-01-01

  including rules to enforce the requirements of this section. V. Nothing in this section shall be construed to alter the jurisdiction or authority of the board of pharmacy under RSA 318. 126-ZZ:7 Free Care and Public Benefits. I. Each licensed experimental treatment center shall allocate 2 percent of its net annual profits to support access to experimental treatments and health care for qualifyin

• 318:1 · repeal · effective 2027-01-01

  the drug and pharmaceutical care activities. No person shall alter, deface, or remove any label so affixed. 6 Pharmacists and Pharmacies; Definitions; Practice of Pharmacy. RSA 318:1, XIV is repealed and reenacted to read as follows: XIV.(a) "Practice of pharmacy" means the scope of practice for the provision of patient care services by a pharmacist shall be based on their education, training, a

• 318:15-D · amend · effective 2027-01-01

  all at all times be [exposed in a conspicuous place] posted in the pharmacy for which it is issued. 4 Pharmacists and Pharmacies; Licensed Pharmacists; Remote Processing. Amend RSA 318:15-d, I to read as follows: I. New Hampshire licensed pharmacists, licensed advanced pharmacy technicians, certified New Hampshire pharmacy technicians, or registered New Hampshire pharmacy interns may engage in remote p

• 318:16-A · reference · effective 2027-01-01

  medication therapy management; (5) The participation in collaborative pharmacy practice and collaborative pharmacy practice agreements as defined in RSA 318:1, XXVI - XXVII, and RSA 318:16-a; (6) The prescribing, ordering, administering, and interpretation of laboratory tests, controlled and noncontrolled drugs, and devices in accordance with applicable state and federal law; (7) The education and couns

• 318:16-B · amend · effective 2027-01-01

  ould be provided in a similar setting by a reasonable and prudent individual with similar education, training, and experience. 13 Pharmacist Administration of Vaccines. Amend RSA 318:16-b, II to read as follows: II. A pharmacist, pharmacy intern, [or] licensed advanced pharmacy technician, or certified pharmacy technician, under the supervision of an on-site immunizing pharmacist may administer vacci

• 318:19 · amend · effective 2027-01-01

  pt of approval by the board of pharmacy.] 9 Pharmacy Board; Rulemaking; Examinations. Amend RSA 318:5-a, IV(a) to read as follows: (a) The subjects to be tested pursuant to RSA 318:19; 10 Pharmacy Board; Rulemaking; Licensed Advanced Pharmacy Technicians. Amend RSA 318:5-a, XI-c(a) to read as follows: (a) Requirements for licensure, including experience and education requirements. Any examina

• 318:28 · amend · effective 2027-01-01

  in a way consistent with United States Pharmacopeia standards as well as all relevant state and federal laws or rules. 2 Pharmacists and Pharmacies; Display of Licenses. Amend RSA 318:28 to read as follows: 318:28 [Display] Availability of Licenses. All licenses as pharmacists shall [at all times be conspicuously displayed] be readily retrievable in the pharmacy where the licensee is engaged as suc

• 318:39 · amend · effective 2027-01-01

  l times be conspicuously displayed] be readily retrievable in the pharmacy where the licensee is engaged as such. 3 Pharmacists and Pharmacies; Licensure of Pharmacies. Amend RSA 318:39 to read as follows: 318:39 Application; Display. Application for a permit shall be made in such manner and in such form as the board may determine. The permit shall at all times be [exposed in a conspicuous place]

RSAs mentioned by this document

• RSA 126-A · DEPARTMENT OF HEALTH AND HUMAN SERVICES
• RSA 126-Z · RIGHT TO TRY ACT
• RSA 130-A · LEAD PAINT POISONING PREVENTION AND CONTROL
• RSA 151 · RESIDENTIAL CARE AND HEALTH FACILITY LICENSING
• RSA 167 · PUBLIC ASSISTANCE TO BLIND, AGED, OR DISABLED PERSONS, AND TO DEPENDENT CHILDREN
• RSA 171-A · SERVICES FOR THE DEVELOPMENTALLY DISABLED
• RSA 176-A · ALCOHOL ABUSE PREVENTION AND TREATMENT FUND
• RSA 318 · PHARMACISTS AND PHARMACIES
• RSA 126-A:84 · Opioid Abatement Trust Fund; Management and Distribution of Funds
• RSA 126-Z:1 · Definitions
• RSA 126-Z:3 · Liability of Physician; Facility
• RSA 126-Z:6 · Telehealth Prescreening
• RSA 126-Z:8 · Statutory Construction
• RSA 130-A:15 · Lead Poisoning Prevention Fund
• RSA 151:2 · License or Registration Required
• RSA 167:64 · Uncompensated Care and Medicaid Fund; Disproportionate Share Hospital Fund
• RSA 176-A:1 · Addiction, Treatment, and Prevention Fund
• RSA 318:1 · Definitions
• RSA 318:19 · Examinations
• RSA 318:28 · Display of Licenses
• RSA 318:39 · Application; Display